Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Vaccines

Free Subscription 16.03.2026 1 Ann Intern Med 2 Clin Infect Dis 1 J Immunol 2 J Infect 5 J Infect Dis 1 JAMA 3 MMWR Morb Mortal Wkly Rep 1 N Engl J Med 3 Nat Immunol 3 Nat Med 3 Pediatr Infect Dis J 5 Pediatrics 1 PLoS Biol 5 PLoS One 42 Vaccine 1 Virology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Intern Med

1. LALANI HS, DiResta R, Baron RJ, Scales D, et al
   Addressing Viral Medical Rumors and False or Misleading Information.
   Ann Intern Med. 2023 Jul 18. doi: 10.7326/M23-1218.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

2. ATHAN E, Greenberg RN, Baker DA, Shah R, et al
   Safety, Efficacy, and Immunogenicity of a Multivalent Adjuvanted S. aureus Vaccine in Adults with Recent Skin And Soft Tissue Infections: An Observer-blind, Randomized, Placebo-controlled, Multinational Phase 1/2 Trial.
   Clin Infect Dis. 2026 Mar 9:ciag162. doi: 10.1093.
   PubMed         Abstract available
   
   
3. WEE LE, Pang D, Chiew C, Tan J, et al
   Long-term real-world protection afforded by third mRNA doses against symptomatic SARS-COV-2 infections, COVID-19-related emergency attendances and hospitalizations amongst older Singaporeans during an Omicron XBB wave.
   Clin Infect Dis. 2023 Jun 6:ciad345. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Immunol

4. KANTHETI U, Shirley JL, Fry LG, Qvale AM, et al
   PD-L1 cell-intrinsic signals limit immune activation during cutaneous vaccinia virus infection.
   J Immunol. 2026;215:vkaf368.
   PubMed         Abstract available
   
   

   
   J Infect

5. TAMRAKAR D, Shahi SB, Jung E, Naga S, et al
   Effectiveness of the TYPHIBEV(R) (Vi-CRM197 conjugate) Vaccine Introduction in Nepal: A Test-Negative, Case-Control Study.
   J Infect. 2026 Mar 8:106719. doi: 10.1016/j.jinf.2026.106719.
   PubMed         Abstract available
   
   
6. OSMAN S, Science M, McLachlan E, Severini A, et al
   Assessing measles immunity in individuals of childbearing age in Toronto, Ontario, Canada.
   J Infect. 2026;92:106701.
   PubMed         Abstract available
   
   

   
   J Infect Dis

7. TAN YY, Ho RWL, Lim JT, Chiew CJ, et al
   Real-world effectiveness of sequential pneumococcal vaccination in older adults: a cohort study.
   J Infect Dis. 2026 Mar 6:jiag147. doi: 10.1093.
   PubMed         Abstract available
   
   
8. TRAMUTO F, Randazzo G, Santino A, Sferlazza G, et al
   Indirect effect of pneumococcal conjugate vaccines on pneumococcal colonization: persistence and dynamics of vaccine serotypes in Sicily (Italy) eleven years post-introduction, 2009 to 2020.
   J Infect Dis. 2026 Mar 7:jiag150. doi: 10.1093.
   PubMed         Abstract available
   
   
9. AREGAY A, Friese J, Porrez S, Leroux-Roels I, et al
   Induction of a Th1-Type Polyfunctional T Cell Response by the four-segmented Rift Valley Fever candidate vaccine in humans.
   J Infect Dis. 2026 Mar 9:jiag138. doi: 10.1093.
   PubMed         Abstract available
   
   
10. BAILEY AL, Stapleton JT
    Time for a New Yellow Fever Vaccine.
    J Infect Dis. 2026 Mar 9:jiag152. doi: 10.1093.
    PubMed        
    
    
11. ONG DS, Toh ZQ, Temple B, Nguyen CD, et al
    Serotype-specific immunity and association with pneumococcal carriage following 3+1, 3+0 and 2+1 schedules of 10-valent pneumococcal conjugate vaccine.
    J Infect Dis. 2026 Mar 12:jiag157. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    JAMA

12. WANG L, Nangle SJ, Waller-Pulido A, McMahan K, et al
    Vaccine-Elicited Antibody Responses to Influenza A(H3N2) Subclade K.
    JAMA. 2026 Mar 9:e262173. doi: 10.1001/jama.2026.2173.
    PubMed        
    
    

    
    MMWR Morb Mortal Wkly Rep

13. MALONEY P, Reeves EL, Wielgosz K, Price AM, et al
    Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026.
    MMWR Morb Mortal Wkly Rep. 2026;75:116-123.
    PubMed         Abstract available
    
    
14. ZHU S, Quint J, Leon TM, Li NJ, et al
    Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - California, October 2025-January 2026.
    MMWR Morb Mortal Wkly Rep. 2026;75:124-128.
    PubMed         Abstract available
    
    
15. STANISLAWSKI E, Romero A, Holzinger N, Healy R, et al
    Measles Outbreak - New Mexico, 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:111-115.
    PubMed         Abstract available
    
    

    
    N Engl J Med

16. 
    Current and Emerging Approaches to Evaluating Influenza Vaccine Performance.
    N Engl J Med. 2026;394:1144.
    PubMed        
    
    

    
    Nat Immunol

17. FRISCHHOLZ S, Schuster EM, Grotz M, Schulein C, et al
    Metabolic quiescence of naive-like memory T cells precedes and maintains antigen-specific T cell memory.
    Nat Immunol. 2026;27:452-462.
    PubMed         Abstract available
    
    
18. GIESELMANN L, DeLaitsch AT, Rohde M, Radford C, et al
    Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332(gp120) glycan-independent epitope.
    Nat Immunol. 2026;27:572-585.
    PubMed         Abstract available
    
    
19. PAINTER MM, Johnston TS, Lundgreen KA, Santos JJS, et al
    Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection.
    Nat Immunol. 2023;24:1711-1724.
    PubMed         Abstract available
    
    

    
    Nat Med

20. PLOQUIN A, Mason RD, Holman LA, Happe M, et al
    A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial.
    Nat Med. 2026 Mar 12. doi: 10.1038/s41591-026-04265.
    PubMed         Abstract available
    
    
21. HAANEN JB, Schumacher TNM, Kagan JC, Fritsch EF, et al
    Clinical development of cancer vaccines.
    Nat Med. 2026 Mar 11. doi: 10.1038/s41591-026-04241.
    PubMed         Abstract available
    
    
22. MAY M
    Mosquito-borne viruses, vaccine-borne hope.
    Nat Med. 2026 Mar 9. doi: 10.1038/d41591-026-00014.
    PubMed        
    
    

    
    Pediatr Infect Dis J

23. KAPLAN SL, Barson WJ, Ling Lin P, Dahl S, et al
    Invasive Pneumococcal Disease at Eight Children's Hospitals in the United States, 2018-2023.
    Pediatr Infect Dis J. 2026;45:300-306.
    PubMed         Abstract available
    
    
24. WOSITZKY M, Louise J, D'Angelo N, Wood N, et al
    Invasive Meningococcal Disease in Australian Children 2016-2022: A Multicenter, Prospective Surveillance Study of Serogroup Distribution and Clinical Presentation in the Meningococcal Vaccine Era.
    Pediatr Infect Dis J. 2026 Mar 10. doi: 10.1097/INF.0000000000005214.
    PubMed         Abstract available
    
    
25. GENTILE A, Juarez MDV, Lucion MF, Ensinck G, et al
    Impact of Maternal Immunization Against Respiratory Syncytial Virus on Hospitalizations Due to Lower Respiratory Tract Infections in Infants: A Multicenter Study in Argentina.
    Pediatr Infect Dis J. 2026;45:307-311.
    PubMed         Abstract available
    
    

    
    Pediatrics

26. GASCHIGNARD J, Koehl B, Rees DC, Rincon-Lopez E, et al
    Invasive Bacterial Infections in Children With Sickle Cell Disease: 2014-2019.
    Pediatrics. 2023;152:e2022061061.
    PubMed         Abstract available
    
    
27. YAN AP, Archer NM, Arnold D, Hansbury E, et al
    Increasing COVID-19 Vaccination Rates for Children With Sickle Cell Disease.
    Pediatrics. 2023;152:e2022061011.
    PubMed         Abstract available
    
    
28. RESTREPO J, Herrera T, Samakoses R, Reina JC, et al
    Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety.
    Pediatrics. 2023;152:e2022060993.
    PubMed         Abstract available
    
    
29. 
    Recommendations for Prevention and Control of Influenza in Children, 2023-2024.
    Pediatrics. 2023 Aug 29:e2023063773. doi: 10.1542/peds.2023-063773.
    PubMed         Abstract available
    
    
30. 
    Recommendations for Prevention and Control of Influenza in Children, 2023-2024.
    Pediatrics. 2023 Aug 29:e2023063772. doi: 10.1542/peds.2023-063772.
    PubMed         Abstract available
    
    

    
    PLoS Biol

31. KENNEDY DA
    Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution.
    PLoS Biol. 2026;24:e3003701.
    PubMed         Abstract available
    
    

    
    PLoS One

32. ANTUNES L, Nunes B, Nunez O, Martinez-Baz I, et al
    Modelling approaches for estimating vaccine effectiveness of consecutive SARS-CoV-2 variant sublineages in the absence of study-specific genetic sequencing data, VEBIS hospital network, Europe, 2023/24.
    PLoS One. 2026;21:e0343988.
    PubMed         Abstract available
    
    
33. SOGBESAN A, Bakare AA, Herzig van Wees S, Salako J, et al
    Exploring COVID-19 pandemic perceptions and vaccine uptake among community members and primary healthcare workers in Nigeria: A mixed methods study.
    PLoS One. 2026;21:e0310437.
    PubMed         Abstract available
    
    
34. LAU HC, Sekawi Z, Ching SM, Abu Bakar N, et al
    Effectiveness of the influenza and Tdap vaccination educational module (InTroDuce-Programme) on knowledge and intention for antenatal vaccination: A cluster randomised controlled trial protocol among pregnant women in Malaysian primary care clinics.
    PLoS One. 2026;21:e0344651.
    PubMed         Abstract available
    
    
35. JONES M, Reilly M, Simanek A, Stewart A, et al
    A randomized assessment of the impact of 'Those Nerdy Girls' newsletters on adult vaccination outcomes.
    PLoS One. 2026;21:e0344258.
    PubMed         Abstract available
    
    
36. PALMER D, Shemshadian A, Berman K, Nobles A, et al
    An Fc-silent OspA monoclonal antibody passively protects mice from tick and intradermal Borrelia burgdorferi challenge.
    PLoS One. 2026;21:e0339749.
    PubMed         Abstract available
    
    

    
    Vaccine

37. MEERAUS W, Stuurman AL, Durukal I, Conde-Sousa E, et al
    COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron.
    Vaccine. 2023;41:6366-6378.
    PubMed         Abstract available
    
    
38. FULLER HR, Huseth-Zosel A, Vleet BV, Hajdar M, et al
    Vaccine attitudes and acceptance among older adults in North Dakota: Understanding demographic characteristic variability.
    Vaccine. 2023;41:6350-6358.
    PubMed         Abstract available
    
    
39. YU J, Sreenivasan C, Sheng Z, Zhai SL, et al
    A recombinant chimeric influenza virus vaccine expressing the consensus H3 hemagglutinin elicits broad hemagglutination inhibition antibodies against divergent swine H3N2 influenza viruses.
    Vaccine. 2023 Sep 7:S0264-410X(23)01060-5. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
    
40. VAUX S, Gautier A, Nassany O, Bonmarin I, et al
    Vaccination acceptability in the French general population and related determinants, 2000-2021.
    Vaccine. 2023;41:6281-6290.
    PubMed         Abstract available
    
    
41. YASUGI M, Nakagama Y, Kaku N, Nitahara Y, et al
    Characteristics of epitope dominance pattern and cross-variant neutralisation in 16 SARS-CoV-2 mRNA vaccine sera.
    Vaccine. 2023;41:6248-6254.
    PubMed         Abstract available
    
    
42. ALSAIF F, Twigg M, Scott S, Blyth A, et al
    A systematic review of barriers and enablers associated with uptake of influenza vaccine among care home staff.
    Vaccine. 2023 Sep 4:S0264-410X(23)01048-4. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
    
43. DUPLESSIS C, Clarkson KA, Ross Turbyfill K, Alcala AN, et al
    GMP manufacture of Shigella flexneri 2a Artificial Invaplex (Invaplex(AR)) and evaluation in a Phase 1 Open-label, dose escalating study administered intranasally to healthy, adult volunteers.
    Vaccine. 2023;41:6261-6271.
    PubMed         Abstract available
    
    
44. JACOBS ET, Cordova-Marks FM, Farland LV, Ernst KC, et al
    Understanding low COVID-19 booster uptake among US adults.
    Vaccine. 2023;41:6221-6226.
    PubMed         Abstract available
    
    
45. DA PENHA GOMES GOUVEA M, Lira Machado KLL, de Oliveira YGP, Moulaz IR, et al
    Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose.
    Vaccine. 2023;41:6514-6528.
    PubMed         Abstract available
    
    
46. KRISHNA SUSARLA S, Jahagirdar R, Ghosh Uttam K, Srikanth Bhatt S, et al
    Immunogenicity and safety of Mebella vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority study.
    Vaccine. 2023;41:6558-6564.
    PubMed         Abstract available
    
    
47. YESKENDIR A, Gusmanov A, Zhussupov B
    Parental attitudes, beliefs and behaviors toward childhood and COVID-19 vaccines: A countrywide survey conducted in Kazakhstan examining vaccine refusal and hesitancy.
    Vaccine. 2023;41:6548-6557.
    PubMed         Abstract available
    
    
48. WATLE SV, Borud B, Laake I, Baranowska-Hustad M, et al
    Antibodies against Neisseria meningitidis serogroups A, C, W and Y in serum and saliva of Norwegian adolescents.
    Vaccine. 2023;41:6529-6537.
    PubMed         Abstract available
    
    
49. ZHANG J, Zhang Z, Yang D, Ren Q, et al
    Combination of lytic phage Sal-P001 and RAST002 vaccine induces complete protection against homologous and heterologous Salmonella strains.
    Vaccine. 2026;79:128451.
    PubMed         Abstract available
    
    
50. ALLEN JD, Caetano C, Sands CM, Medina JM, et al
    Synthetic TRAC478 emulsion and saponin based adjuvant systems enhance humoral and cellular immune responses elicited by computationally optimized H1 and H3 hemagglutinin subunit vaccines.
    Vaccine. 2026;79:128421.
    PubMed         Abstract available
    
    
51. CABIESES B, Obach A, Madrid P, Blukacz A, et al
    Mapping the continuum of COVID-19 vaccine acceptance and hesitancy in Chile: Insights from qualitative research among nationals and migrants.
    Vaccine. 2026;79:128433.
    PubMed         Abstract available
    
    
52. ZHANG X, Wang H, Li K, Wang X, et al
    Dehydroevodiamine enhances PEDV vaccine efficacy through immune-gut microbiota modulation.
    Vaccine. 2026;79:128411.
    PubMed         Abstract available
    
    
53. MESLE MMI, Jorgensen P, Barakat A, Herring BL, et al
    Influenza vaccine recommendations and coverage (2018-2023): a foundation for pandemic preparedness and response.
    Vaccine. 2026;78:128391.
    PubMed         Abstract available
    
    
54. LU PJ, Hung MC, Srivastav A, Kriss JL, et al
    RSV vaccination uptake by the end of the 2024-25 respiratory virus season among adults aged 60-74 years at increased risk of severe RSV and adults aged >/=75 years.
    Vaccine. 2026;79:128427.
    PubMed         Abstract available
    
    
55. BONI S, Quessette M, Nedelec E, Akotangni E, et al
    Human papillomavirus vaccine uptake among adolescent girls living with HIV in Cote d'Ivoire: A national cross-sectional survey.
    Vaccine. 2026;79:128434.
    PubMed         Abstract available
    
    
56. WAGNER SB, Malherbe DC, Napier EG, Marzi A, et al
    Glycoprotein-specific transcriptional response contributes to differential vaccine protection against lethal Ebola virus infection.
    Vaccine. 2026;79:128410.
    PubMed         Abstract available
    
    
57. GURRY C, Okot C, Nardone A, Akpaka K, et al
    The AFRO-MoVE network: COVID-19 vaccine research in Africa.
    Vaccine. 2026 Mar 11:128370. doi: 10.1016/j.vaccine.2026.128370.
    PubMed        
    
    
58. NILYANIMIT P, Suntronwong N, Puenpa J, Thongmee T, et al
    Strengthening measles immunity in Thailand: Rationale for a third vaccine dose to avert outbreaks.
    Vaccine. 2026;79:128438.
    PubMed         Abstract available
    
    
59. VISKUPIC F, Wiltse DL, Liebl Z, Kinslow T, et al
    The prevalence and nature of anti-vaccination legislation in ten midwestern states: Implications for public health and policy.
    Vaccine. 2026;79:128452.
    PubMed         Abstract available
    
    
60. MALLAH N, Pardo-Seco J, Rodriguez-Tenreiro-Sanchez C, Gine-Vazquez I, et al
    Methods and operational framework of GALFLU: Individually randomized pragmatic controlled trial of high- versus standard-dose influenza vaccination in older adults.
    Vaccine. 2026;79:128435.
    PubMed         Abstract available
    
    
61. GUARDALINI LGO, Martins IM, Bernardino TC, Quintilio W, et al
    Non-clinical analysis of virus-like particles (VLP) containing SARS-CoV-2 vaccine antigens.
    Vaccine. 2026;79:128406.
    PubMed         Abstract available
    
    
62. SORDO-PUGA Y, Sardina-Gonzalez T, Mendez-Orta MK, Hernandez-Garcia M, et al
    Post-licensing evaluation of Porvac(R) subunit vaccine against classical swine fever in two pig genetic development farms in Cuba.
    Vaccine. 2026;78:128386.
    PubMed         Abstract available
    
    
63. STEFANIA B, Flavia P, Antonio P, Emanuele P, et al
    Impact of pharmacy-based interventions on vaccination coverage among vulnerable and underserved populations: a systematic review and meta-analysis.
    Vaccine. 2026;78:128426.
    PubMed         Abstract available
    
    
64. SONG Y, Li R, Guo H
    Senescent Cancer cell-derived vaccines: Current Progress, immunological challenges, and translational perspectives.
    Vaccine. 2026;79:128430.
    PubMed         Abstract available
    
    
65. DUDASOVA J, Valenta Z, Magalie A, Nieddu GT, et al
    Annual immunogenicity measurements in randomized clinical trials help reveal heterogeneity in long-term vaccine efficacy: a pooled logistic regression modeling study.
    Vaccine. 2026;78:128326.
    PubMed         Abstract available
    
    
66. PECONICK AP, Kalks KHM, Tafur-Gomez GA, Alves BH, et al
    Recombinant immunogen rBm7462 expressed in a transgenic plant (Arabidopsis thaliana) as a new approach for Rhipicephalus microplus vaccine.
    Vaccine. 2026;78:128422.
    PubMed         Abstract available
    
    
67. MENANG O, Gambo M, Keoulon KC, Babale SM, et al
    Enhanced passive safety surveillance during the first use of the meningococcal vaccine A/C/W/Y/X conjugate for outbreak response in Niger and Nigeria.
    Vaccine. 2026;79:128390.
    PubMed         Abstract available
    
    
68. DE COUVREUR LA, Cobo MJ, Kennedy PJ, Ellis JT, et al
    Bibliometric analysis of parasite vaccine research from 1990 to 2019.
    Vaccine. 2023;41:6468-6477.
    PubMed         Abstract available
    
    
69. TSIRIGOTAKI M, Galanakis E
    Impact of vaccines on Staphylococcus aureus colonization: A systematic review and meta-analysis.
    Vaccine. 2023;41:6478-6487.
    PubMed         Abstract available
    
    
70. NUSSBAUM J, Cao X, Railkar RA, Sachs JR, et al
    Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults.
    Vaccine. 2023;41:6488-6501.
    PubMed         Abstract available
    
    
71. SALO H, Perala J, Hannila-Handelberg T, Sarvikivi E, et al
    Decline in varicella cases contacting primary health care after introduction of varicella vaccination in Finland - A population-based register study.
    Vaccine. 2023;41:6535-6541.
    PubMed         Abstract available
    
    
72. MATHUR I, Church R, Ruisch A, Noyes K, et al
    Insights to COVID-19 vaccine delivery: Results from a survey of 27 countries.
    Vaccine. 2023;41:6406-6410.
    PubMed         Abstract available
    
    
73. JALALIZADEH M, Leme PAF, Buosi K, Dionato FAV, et al
    Healthcare Workers (HCWs) and non-HCWs reaction to Bacillus Calmette-Guerin (BCG) in the BATTLE trial.
    Vaccine. 2023;41:6599-6606.
    PubMed         Abstract available
    
    
74. HOMAIRA N, He WQ, McRae J, Macartney K, et al
    Coverage and predictors of influenza and pertussis vaccination during pregnancy: a whole of population-based study.
    Vaccine. 2023 Sep 21:S0264-410X(23)01062-9. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
    
75. SANADA T, Oda Y, Ohashi C, Isotani K, et al
    Hybrid large hepatitis B surface protein composed of two viral genotypes C and D induces strongly cross-neutralizing antibodies.
    Vaccine. 2023 Sep 20:S0264-410X(23)01096-4. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
    
76. LASSAUNIERE R, Polacek C, Linnea Tingstedt J, Fomsgaard A, et al
    Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine.
    Vaccine. 2023;41:6505-6513.
    PubMed         Abstract available
    
    
77. WANG Y, Ji W, Li D, Sun T, et al
    Active inoculation with an inactivated Coxsackievirus A2 vaccine induces neutralizing antibodies and protects mice against lethal infection.
    Vaccine. 2023;41:6470-6482.
    PubMed         Abstract available
    
    
78. JI WY, Liu DL, Yu R, Miao L, et al
    Vaccination coverage survey of children aged 1-3 years in Beijing, China, 2005-2021.
    Vaccine. 2023;41:6444-6452.
    PubMed         Abstract available
    
    

    
    Virology

79. NIU S, Guo Y, Wang X, Wang Z, et al
    Innate immune escape and adaptive immune evasion of African swine fever virus: A review.
    Virology. 2023;587:109878.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum